Search

Your search keyword '"Omenn, Gilbert S."' showing total 1,812 results
Start Over Author "Omenn, Gilbert S."
1,812 results on '"Omenn, Gilbert S."'

51. The Beta-Carotene and Retinol Efficacy Trial: Incidence of Lung Cancer and Cardiovascular Disease Mortality During 6-Year Follow-up After Stopping β-Carotene and Retinol Supplements

Author

Goodman, Gary E, Thornquist, Mark D, Balmes, John, Cullen, Mark R, Meyskens, Frank L, Omenn, Gilbert S, Valanis, Barbara, and Williams, James H

Subjects
Clinical Trials and Supportive Activities, Tobacco, Cancer, Lung, Clinical Research, Prevention, Lung Cancer, Tobacco Smoke and Health, Respiratory, Good Health and Well Being, Adult, Aged, Anticarcinogenic Agents, Carcinogens, Cardiovascular Diseases, Confidence Intervals, Female, Follow-Up Studies, Humans, Incidence, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Sex Factors, United States, beta Carotene, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundThe Beta-Carotene and Retinol Efficacy Trial (CARET) tested the effect of daily beta-carotene (30 mg) and retinyl palmitate (25,000 IU) on the incidence of lung cancer, other cancers, and death in 18,314 participants who were at high risk for lung cancer because of a history of smoking or asbestos exposure. CARET was stopped ahead of schedule in January 1996 because participants who were randomly assigned to receive the active intervention were found to have a 28% increase in incidence of lung cancer, a 17% increase in incidence of death and a higher rate of cardiovascular disease mortality compared with participants in the placebo group.MethodsAfter the intervention ended, CARET participants returned the study vitamins to their study center and provided a final blood sample. They continue to be followed annually by telephone and mail self-report. Self-reported cancer endpoints were confirmed by review of pathology reports, and death endpoints were confirmed by review of death certificates. All statistical tests were two-sided.ResultsWith follow-up through December 31, 2001, the post-intervention relative risks of lung cancer and all-cause mortality for the active intervention group compared with the placebo group were 1.12 (95% confidence interval [CI] = 0.97 to 1.31) and 1.08 (95% CI = 0.99 to 1.17), respectively. Smoothed relative risk curves for lung cancer incidence and all-cause mortality indicated that relative risks remained above 1.0 throughout the post-intervention follow-up. By contrast, the relative risk of cardiovascular disease mortality decreased rapidly to 1.0 after the intervention was stopped. During the post-intervention phase, females had larger relative risks of lung cancer mortality (1.33 versus 1.14; P = .36), cardiovascular disease mortality (1.44 versus 0.93; P = .03), and all-cause mortality (1.37 versus 0.98; P = .001) than males.ConclusionsThe previously reported adverse effects of beta-carotene and retinyl palmitate on lung cancer incidence and all-cause mortality in cigarette smokers and individuals with occupational exposure to asbestos persisted after drug administration was stopped although they are no longer statistically significant. Planned subgroup analyses suggest that the excess risks of lung cancer were restricted primarily to females, and cardiovascular disease mortality primarily to females and to former smokers.

Published
2004

52. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.

Author

Goodman, Gary E, Thornquist, Mark D, Balmes, John, Cullen, Mark R, Meyskens, Frank L, Omenn, Gilbert S, Valanis, Barbara, and Williams, James H

Subjects
Humans, Lung Neoplasms, Cardiovascular Diseases, beta Carotene, Anticarcinogenic Agents, Carcinogens, Incidence, Confidence Intervals, Risk Assessment, Risk Factors, Follow-Up Studies, Sex Factors, Adult, Aged, Middle Aged, United States, Female, Male, Randomized Controlled Trials as Topic, Clinical Research, Lung, Clinical Trials and Supportive Activities, Lung Cancer, Prevention, Tobacco, Cancer, Tobacco Smoke and Health, Respiratory, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

BackgroundThe Beta-Carotene and Retinol Efficacy Trial (CARET) tested the effect of daily beta-carotene (30 mg) and retinyl palmitate (25,000 IU) on the incidence of lung cancer, other cancers, and death in 18,314 participants who were at high risk for lung cancer because of a history of smoking or asbestos exposure. CARET was stopped ahead of schedule in January 1996 because participants who were randomly assigned to receive the active intervention were found to have a 28% increase in incidence of lung cancer, a 17% increase in incidence of death and a higher rate of cardiovascular disease mortality compared with participants in the placebo group.MethodsAfter the intervention ended, CARET participants returned the study vitamins to their study center and provided a final blood sample. They continue to be followed annually by telephone and mail self-report. Self-reported cancer endpoints were confirmed by review of pathology reports, and death endpoints were confirmed by review of death certificates. All statistical tests were two-sided.ResultsWith follow-up through December 31, 2001, the post-intervention relative risks of lung cancer and all-cause mortality for the active intervention group compared with the placebo group were 1.12 (95% confidence interval [CI] = 0.97 to 1.31) and 1.08 (95% CI = 0.99 to 1.17), respectively. Smoothed relative risk curves for lung cancer incidence and all-cause mortality indicated that relative risks remained above 1.0 throughout the post-intervention follow-up. By contrast, the relative risk of cardiovascular disease mortality decreased rapidly to 1.0 after the intervention was stopped. During the post-intervention phase, females had larger relative risks of lung cancer mortality (1.33 versus 1.14; P = .36), cardiovascular disease mortality (1.44 versus 0.93; P = .03), and all-cause mortality (1.37 versus 0.98; P = .001) than males.ConclusionsThe previously reported adverse effects of beta-carotene and retinyl palmitate on lung cancer incidence and all-cause mortality in cigarette smokers and individuals with occupational exposure to asbestos persisted after drug administration was stopped although they are no longer statistically significant. Planned subgroup analyses suggest that the excess risks of lung cancer were restricted primarily to females, and cardiovascular disease mortality primarily to females and to former smokers.

Published
2004

54. Abstract 3127: Comprehensive proteogenomic characterization of rare kidney tumors

Author

Li, Ginny Xiaohe, primary, Hsiao, Yi, additional, Chen, Lijun, additional, Mannan, Rahul, additional, Zhang, Yuping, additional, Petralia, Francesca, additional, Cho, Hanbyul, additional, Hosseini, Noshad, additional, Calinawan, Anna, additional, Li, Yize, additional, Anand, Shankara, additional, Dagar, Aniket, additional, Geffen, Yifat, additional, Leprevost, Felipe V., additional, Le, Anne, additional, Ponce, Sean, additional, Schnaubelt, Michael, additional, Deen, Nataly Naser Al, additional, Caravan, Wagma, additional, Houston, Andrew, additional, Kumar-Sinha, Chandan, additional, Wang, Xiaoming, additional, Chugh, Seema, additional, Omenn, Gilbert S., additional, Chan, Daniel W., additional, Ricketts, Christopher, additional, Mehra, Rohit, additional, Chinnaiyan, Arul, additional, Ding, Li, additional, Cieslik, Marcin, additional, Zhang, Hui, additional, Dhanasekaran, Saravana M., additional, and Nesvizhskii, Alexey I., additional

Published
2023
Full Text
View/download PDF

55. Data from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer

Author

Wang, Xiao-Song, primary, Shankar, Sunita, primary, Dhanasekaran, Saravana M., primary, Ateeq, Bushra, primary, Sasaki, Atsuo T., primary, Jing, Xiaojun, primary, Robinson, Daniel, primary, Cao, Qi, primary, Prensner, John R., primary, Yocum, Anastasia K., primary, Wang, Rui, primary, Fries, Daniel F., primary, Han, Bo, primary, Asangani, Irfan A., primary, Cao, Xuhong, primary, Li, Yong, primary, Omenn, Gilbert S., primary, Pflueger, Dorothee, primary, Gopalan, Anuradha, primary, Reuter, Victor E., primary, Kahoud, Emily Rose, primary, Cantley, Lewis C., primary, Rubin, Mark A., primary, Palanisamy, Nallasivam, primary, Varambally, Sooryanarayana, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

58. Supplementary Methods and Data (posted 7/5/2011) from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer

Author

Wang, Xiao-Song, primary, Shankar, Sunita, primary, Dhanasekaran, Saravana M., primary, Ateeq, Bushra, primary, Sasaki, Atsuo T., primary, Jing, Xiaojun, primary, Robinson, Daniel, primary, Cao, Qi, primary, Prensner, John R., primary, Yocum, Anastasia K., primary, Wang, Rui, primary, Fries, Daniel F., primary, Han, Bo, primary, Asangani, Irfan A., primary, Cao, Xuhong, primary, Li, Yong, primary, Omenn, Gilbert S., primary, Pflueger, Dorothee, primary, Gopalan, Anuradha, primary, Reuter, Victor E., primary, Kahoud, Emily Rose, primary, Cantley, Lewis C., primary, Rubin, Mark A., primary, Palanisamy, Nallasivam, primary, Varambally, Sooryanarayana, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

59. Supplementary Methods, Figures, Tables, and References from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer

Author

Wang, Xiao-Song, primary, Shankar, Sunita, primary, Dhanasekaran, Saravana M., primary, Ateeq, Bushra, primary, Sasaki, Atsuo T., primary, Jing, Xiaojun, primary, Robinson, Daniel, primary, Cao, Qi, primary, Prensner, John R., primary, Yocum, Anastasia K., primary, Wang, Rui, primary, Fries, Daniel F., primary, Han, Bo, primary, Asangani, Irfan A., primary, Cao, Xuhong, primary, Li, Yong, primary, Omenn, Gilbert S., primary, Pflueger, Dorothee, primary, Gopalan, Anuradha, primary, Reuter, Victor E., primary, Kahoud, Emily Rose, primary, Cantley, Lewis C., primary, Rubin, Mark A., primary, Palanisamy, Nallasivam, primary, Varambally, Sooryanarayana, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

60. The 2022 Report on the Human Proteome from the HUPO Human Proteome Project

Author

Omenn, Gilbert S., Lane, Lydie, Overall, Christopher M., Pineau, Charles, Packer, Nicolle H., Cristea, Ileana M., Lindskog, Cecilia, Weintraub, Susan T., Orchard, Sandra, Roehrl, Michael H. A., Nice, Edouard, Liu, Siqi, Bandeira, Nuno, Chen, Yu-Ju, Guo, Tiannan, Aebersold, Ruedi, Moritz, Robert L., Deutsch, Eric W., Omenn, Gilbert S., Lane, Lydie, Overall, Christopher M., Pineau, Charles, Packer, Nicolle H., Cristea, Ileana M., Lindskog, Cecilia, Weintraub, Susan T., Orchard, Sandra, Roehrl, Michael H. A., Nice, Edouard, Liu, Siqi, Bandeira, Nuno, Chen, Yu-Ju, Guo, Tiannan, Aebersold, Ruedi, Moritz, Robert L., and Deutsch, Eric W.

Abstract

The 2022 Metrics of the Human Proteome from the HUPO Human Proteome Project (HPP) show that protein expression has now been credibly detected (neXtProt PE1 level) for 18 407 (93.2%) of the 19 750 predicted proteins coded in the human genome, a net gain of 50 since 2021 from data sets generated around the world and reanalyzed by the HPP. Conversely, the number of neXtProt PE2, PE3, and PE4 missing proteins has been reduced by 78 from 1421 to 1343. This represents continuing experimental progress on the human proteome parts list across all the chromosomes, as well as significant reclassifications. Meanwhile, applying proteomics in a vast array of biological and clinical studies continues to yield significant findings and growing integration with other omics platforms. We present highlights from the Chromosome-Centric HPP, Biology and Disease-driven HPP, and HPP Resource Pillars, compare features of mass spectrometry and Olink and Somalogic platforms, note the emergence of translation products from ribosome profiling of small open reading frames, and discuss the launch of the initial HPP Grand Challenge Project, “A Function for Each Protein”.

Published
2023
Full Text
View/download PDF

61. DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk

Author

Grasberger, Helmut, Magis, Andrew T., Sheng, Elisa, Conomos, Matthew P., Zhang, Min, Garzotto, Lea S., Hou, Guoqing, Bishu, Shrinivas, Nagao-Kitamoto, Hiroko, Zaatari, Mohamad El-, Kitamoto, Sho, Kamada, Nobuhiko, Stidham, Ryan W., Akiba, Yasutada, Kaunitz, Jonathan, Haberman, Yael, Kugathasan, Subra, Denson, Lee A., Omenn, Gilbert S., and Kao, John Y.

Subjects
Dysbiosis -- Genetic aspects -- Causes of -- Complications and side effects, Inflammatory bowel diseases -- Genetic aspects -- Risk factors, Homeostasis -- Genetic aspects -- Health aspects, Genetic variation -- Research, Immune response -- Regulation, Health care industry
Abstract

A primordial gut-epithelial innate defense response is the release of hydrogen peroxide by dual NADPH oxidase (DUOX). In inflammatory bowel disease (IBD), a condition characterized by an imbalanced gut microbiota-immune homeostasis, DUOX2 isoenzyme is the highest induced gene. Performing multiomic analyses using 2872 human participants of a wellness program, we detected a substantial burden of rare protein-altering DUOX2 gene variants of unknown physiologic significance. We identified a significant association between these rare loss-of-function variants and increased plasma levels of interleukin-17C, which is induced also in mucosal biopsies of patients with IBD. DUOX2-deficient mice replicated increased IL-17C induction in the intestine, with outlier high II17c expression linked to the mucosal expansion of specific Proteobacteria pathobionts. Integrated microbiota/host gene expression analyses in patients with IBD corroborated IL-17C as a marker for epithelial activation by gram-negative bacteria. Finally, the impact of DUOX2 variants on IL-17C induction provided a rationale for variant stratification in case control studies that substantiated DUOX2 as an IBD risk gene. Thus, our study identifies an association of deleterious DUOX2 variants with a preclinical hallmark of disturbed microbiota-immune homeostasis that appears to precede the manifestation of IBD., Introduction A monolayer of epithelial cells covers the intestinal lumen preventing an overt immune response against the normal gut microbiota, while at the same time controlling infection with potentially life-threatening [...]

Published
2021
Full Text
View/download PDF

62. Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy Trial

Author

Omenn, Gilbert S, Goodman, Gary E, Thornquist, Mark D, Balmes, John, Cullen, Mark R, Glass, Andrew, Keogh, James P, Meyskens, Frank L, Valanis, Barbara, Williams, James H, Barnhart, Scott, Cherniack, Martin G, Brodkin, Carl Andrew, and Hammar, Samuel

Subjects
Complementary and Integrative Health, Cancer, Prevention, Nutrition, Tobacco, Clinical Research, Lung, Substance Misuse, Tobacco Smoke and Health, Clinical Trials and Supportive Activities, Lung Cancer, 6.1 Pharmaceuticals, Prevention of disease and conditions, and promotion of well-being, 3.3 Nutrition and chemoprevention, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Anticarcinogenic Agents, Antioxidants, Asbestos, Carcinogens, Diterpenes, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Lung Neoplasms, Male, Proportional Hazards Models, Retinyl Esters, Risk Factors, Smoking, Vitamin A, beta Carotene, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundEvidence has accumulated from observational studies that people eating more fruits and vegetables, which are rich in beta-carotene (a violet to yellow plant pigment that acts as an antioxidant and can be converted to vitamin A by enzymes in the intestinal wall and liver) and retinol (an alcohol chemical form of vitamin A), and people having higher serum beta-carotene concentrations had lower rates of lung cancer. The Beta-Carotene and Retinol Efficacy Trial (CARET) tested the combination of 30 mg beta-carotene and 25,000 IU retinyl palmitate (vitamin A) taken daily against placebo in 18314 men and women at high risk of developing lung cancer. The CARET intervention was stopped 21 months early because of clear evidence of no benefit and substantial evidence of possible harm; there were 28% more lung cancers and 17% more deaths in the active intervention group (active = the daily combination of 30 mg beta-carotene and 25,000 IU retinyl palmitate). Promptly after the January 18, 1996, announcement that the CARET active intervention had been stopped, we published preliminary findings from CARET regarding cancer, heart disease, and total mortality.PurposeWe present for the first time results based on the pre-specified analytic method, details about risk factors for lung cancer, and analyses of subgroups and of factors that possibly influence response to the intervention.MethodsCARET was a randomized, double-blinded, placebo-controlled chemoprevention trial, initiated with a pilot phase and then expanded 10-fold at six study centers. Cigarette smoking history and status and alcohol intake were assessed through participant self-report. Serum was collected from the participants at base line and periodically after randomization and was analyzed for beta-carotene concentration. An Endpoints Review Committee evaluated endpoint reports, including pathologic review of tissue specimens. The primary analysis is a stratified logrank test for intervention arm differences in lung cancer incidence, with weighting linearly to hypothesized full effect at 24 months after randomization. Relative risks (RRs) were estimated by use of Cox regression models; tests were performed for quantitative and qualitative interactions between the intervention and smoking status or alcohol intake. O'Brien-Fleming boundaries were used for stopping criteria at interim analyses. Statistical significance was set at the .05 alpha value, and all P values were derived from two-sided statistical tests.ResultsAccording to CARET's pre-specified analysis, there was an RR of 1.36 (95% confidence interval [CI] = 1.07-1.73; P = .01) for weighted lung cancer incidence for the active intervention group compared with the placebo group, and RR = 1.59 (95% CI = 1.13-2.23; P = .01) for weighted lung cancer mortality. All subgroups, except former smokers, had a point estimate of RR of 1.10 or greater for lung cancer. There are suggestions of associations of the excess lung cancer incidence with the highest quartile of alcohol intake (RR = 1.99; 95% CI = 1.28-3.09; test for heterogeneity of RR among quartiles of alcohol intake has P = .01, unadjusted for multiple comparisons) and with large-cell histology (RR = 1.89; 95% CI = 1.09-3.26; test for heterogeneity among histologic categories has P = .35), but not with base-line serum beta-carotene concentrations.ConclusionsCARET participants receiving the combination of beta-carotene and vitamin A had no chemopreventive benefit and had excess lung cancer incidence and mortality. The results are highly consistent with those found for beta-carotene in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study in 29133 male smokers in Finland.

Published
1996

76. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness

Author

Li, Yize, primary, Lih, Tung-Shing M., additional, Dhanasekaran, Saravana M., additional, Mannan, Rahul, additional, Chen, Lijun, additional, Cieslik, Marcin, additional, Wu, Yige, additional, Lu, Rita Jiu-Hsien, additional, Clark, David J., additional, Kołodziejczak, Iga, additional, Hong, Runyu, additional, Chen, Siqi, additional, Zhao, Yanyan, additional, Chugh, Seema, additional, Caravan, Wagma, additional, Naser Al Deen, Nataly, additional, Hosseini, Noshad, additional, Newton, Chelsea J., additional, Krug, Karsten, additional, Xu, Yuanwei, additional, Cho, Kyung-Cho, additional, Hu, Yingwei, additional, Zhang, Yuping, additional, Kumar-Sinha, Chandan, additional, Ma, Weiping, additional, Calinawan, Anna, additional, Wyczalkowski, Matthew A., additional, Wendl, Michael C., additional, Wang, Yuefan, additional, Guo, Shenghao, additional, Zhang, Cissy, additional, Le, Anne, additional, Dagar, Aniket, additional, Hopkins, Alex, additional, Cho, Hanbyul, additional, Leprevost, Felipe da Veiga, additional, Jing, Xiaojun, additional, Teo, Guo Ci, additional, Liu, Wenke, additional, Reimers, Melissa A., additional, Pachynski, Russell, additional, Lazar, Alexander J., additional, Chinnaiyan, Arul M., additional, Van Tine, Brian A., additional, Zhang, Bing, additional, Rodland, Karin D., additional, Getz, Gad, additional, Mani, D.R., additional, Wang, Pei, additional, Chen, Feng, additional, Hostetter, Galen, additional, Thiagarajan, Mathangi, additional, Linehan, W. Marston, additional, Fenyö, David, additional, Jewell, Scott D., additional, Omenn, Gilbert S., additional, Mehra, Rohit, additional, Wiznerowicz, Maciej, additional, Robles, Ana I., additional, Mesri, Mehdi, additional, Hiltke, Tara, additional, An, Eunkyung, additional, Rodriguez, Henry, additional, Chan, Daniel W., additional, Ricketts, Christopher J., additional, Nesvizhskii, Alexey I., additional, Zhang, Hui, additional, Ding, Li, additional, Francis, Alicia, additional, Paulovich, Amanda G., additional, Antczak, Andrzej, additional, Green, Anthony, additional, Colaprico, Antonio, additional, Hakimi, Ari, additional, Pruetz, Barb, additional, Hindenach, Barbara, additional, Yadav, Birendra Kumar, additional, Reva, Boris, additional, Fevrier-Sullivan, Brenda, additional, Druker, Brian J., additional, Szczylik, Cezary, additional, Goldthwaite, Charles A., additional, Birger, Chet, additional, Jones, Corbin D., additional, Rohrer, Daniel C., additional, Tansil, Darlene, additional, Chesla, David, additional, Heiman, David, additional, Duffy, Elizabeth, additional, Schadt, Eri E., additional, Petralia, Francesca, additional, Bromiński, Gabriel, additional, Quiroga-Garza, Gabriela M., additional, Wilson, George D., additional, Li, Ginny Xiaohe, additional, Zhao, Grace, additional, Hsiao, Yi, additional, Hsieh, James, additional, Lubiński, Jan, additional, Bavarva, Jasmin, additional, Huang, Jasmine, additional, Hafron, Jason, additional, Eschbacher, Jennifer, additional, Hon, Jennifer, additional, Francis, Jesse, additional, Freymann, John, additional, Vo, Josh, additional, Wang, Joshua, additional, Kirby, Justin, additional, Zaalishvili, Kakhaber, additional, Ketchum, Karen A., additional, Hoadley, Katherine A., additional, Um, Ki Sung, additional, Qi, Liqun, additional, Domagalski, Marcin J., additional, Tobin, Matt, additional, Dyer, Maureen, additional, Anurag, Meenakshi, additional, Borucki, Melissa, additional, Gillette, Michael A., additional, Birrer, Michael J., additional, Ittmann, Michael M., additional, Roehrl, Michael H., additional, Schnaubelt, Michael, additional, Smith, Michael, additional, Fam, Mina, additional, Roche, Nancy, additional, Vatanian, Negin, additional, Maunganidze, Nicollette, additional, Potapova, Olga, additional, Paklina, Oxana V., additional, VanderKolk, Pamela, additional, Castro, Patricia, additional, Kurzawa, Paweł, additional, Hariharan, Pushpa, additional, Li, Qin, additional, Li, Qing Kay, additional, Dhir, Rajiv, additional, Thangudu, Ratna R., additional, Montgomery, Rebecca, additional, Smith, Richard D., additional, Mareedu, Sailaja, additional, Payne, Samuel H., additional, Cerda, Sandra, additional, Cottingham, Sandra, additional, Haynes, Sarah, additional, Satpathy, Shankha, additional, Richey, Shannon, additional, Singh, Shilpi, additional, Tsang, Shirley X., additional, Cai, Shuang, additional, Cao, Song, additional, Gabriel, Stacey, additional, Carr, Steven A., additional, Liu, Tao, additional, Bauer, Thomas, additional, Le, Toan, additional, Chen, Xi S., additional, Zhang, Xu, additional, Shutack, Yvonne, additional, and Zhang, Zhen, additional

Published
2023
Full Text
View/download PDF

77. Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study

Author

Tan, Byorn W.L., primary, Tan, Bryce W.Q., additional, Tan, Amelia L.M., additional, Schriver, Emily R., additional, Gutiérrez-Sacristán, Alba, additional, Das, Priyam, additional, Yuan, William, additional, Hutch, Meghan R., additional, García Barrio, Noelia, additional, Pedrera Jimenez, Miguel, additional, Abu-el-rub, Noor, additional, Morris, Michele, additional, Moal, Bertrand, additional, Verdy, Guillaume, additional, Cho, Kelly, additional, Ho, Yuk-Lam, additional, Patel, Lav P., additional, Dagliati, Arianna, additional, Neuraz, Antoine, additional, Klann, Jeffrey G., additional, South, Andrew M., additional, Visweswaran, Shyam, additional, Hanauer, David A., additional, Maidlow, Sarah E., additional, Liu, Mei, additional, Mowery, Danielle L., additional, Batugo, Ashley, additional, Makoudjou, Adeline, additional, Tippmann, Patric, additional, Zöller, Daniela, additional, Brat, Gabriel A., additional, Luo, Yuan, additional, Avillach, Paul, additional, Bellazzi, Riccardo, additional, Chiovato, Luca, additional, Malovini, Alberto, additional, Tibollo, Valentina, additional, Samayamuthu, Malarkodi Jebathilagam, additional, Serrano Balazote, Pablo, additional, Xia, Zongqi, additional, Loh, Ne Hooi Will, additional, Chiudinelli, Lorenzo, additional, Bonzel, Clara-Lea, additional, Hong, Chuan, additional, Zhang, Harrison G., additional, Weber, Griffin M., additional, Kohane, Isaac S., additional, Cai, Tianxi, additional, Omenn, Gilbert S., additional, Holmes, John H., additional, Ngiam, Kee Yuan, additional, Aaron, James R., additional, Agapito, Giuseppe, additional, Albayrak, Adem, additional, Albi, Giuseppe, additional, Alessiani, Mario, additional, Alloni, Anna, additional, Amendola, Danilo F., additional, Angoulvant, François, additional, Anthony, Li L.L.J., additional, Aronow, Bruce J., additional, Ashraf, Fatima, additional, Atz, Andrew, additional, Panickan, Vidul Ayakulangara, additional, Azevedo, Paula S., additional, Balshi, James, additional, Beaulieu-Jones, Brett K., additional, Beaulieu-Jones, Brendin R., additional, Bell, Douglas S., additional, Bellasi, Antonio, additional, Benoit, Vincent, additional, Beraghi, Michele, additional, Bernal-Sobrino, José Luis, additional, Bernaux, Mélodie, additional, Bey, Romain, additional, Bhatnagar, Surbhi, additional, Blanco-Martínez, Alvar, additional, Boeker, Martin, additional, Booth, John, additional, Bosari, Silvano, additional, Bourgeois, Florence T., additional, Bradford, Robert L., additional, Bréant, Stéphane, additional, Brown, Nicholas W., additional, Bruno, Raffaele, additional, Bryant, William A., additional, Bucalo, Mauro, additional, Bucholz, Emily, additional, Burgun, Anita, additional, Cannataro, Mario, additional, Carmona, Aldo, additional, Cattelan, Anna Maria, additional, Caucheteux, Charlotte, additional, Champ, Julien, additional, Chen, Jin, additional, Chen, Krista Y., additional, Cimino, James J., additional, Colicchio, Tiago K., additional, Cormont, Sylvie, additional, Cossin, Sébastien, additional, Craig, Jean B., additional, Cruz-Bermúdez, Juan Luis, additional, Cruz-Rojo, Jaime, additional, Daniar, Mohamad, additional, Daniel, Christel, additional, Devkota, Batsal, additional, Dionne, Audrey, additional, Duan, Rui, additional, Dubiel, Julien, additional, DuVall, Scott L., additional, Esteve, Loic, additional, Estiri, Hossein, additional, Fan, Shirley, additional, Follett, Robert W., additional, Ganslandt, Thomas, additional, García-Barrio, Noelia, additional, Garmire, Lana X., additional, Gehlenborg, Nils, additional, Getzen, Emily J., additional, Geva, Alon, additional, González, Tomás González, additional, Gradinger, Tobias, additional, Gramfort, Alexandre, additional, Griffier, Romain, additional, Griffon, Nicolas, additional, Grisel, Olivier, additional, Guzzi, Pietro H., additional, Han, Larry, additional, Haverkamp, Christian, additional, Hazard, Derek Y., additional, He, Bing, additional, Henderson, Darren W., additional, Hilka, Martin, additional, Honerlaw, Jacqueline P., additional, Huling, Kenneth M., additional, Issitt, Richard W., additional, Jannot, Anne Sophie, additional, Jouhet, Vianney, additional, Kavuluru, Ramakanth, additional, Keller, Mark S., additional, Kennedy, Chris J., additional, Kernan, Kate F., additional, Key, Daniel A., additional, Kirchoff, Katie, additional, Krantz, Ian D., additional, Kraska, Detlef, additional, Krishnamurthy, Ashok K., additional, L'Yi, Sehi, additional, Le, Trang T., additional, Leblanc, Judith, additional, Lemaitre, Guillaume, additional, Lenert, Leslie, additional, Leprovost, Damien, additional, Liu, Molei, additional, Will Loh, Ne Hooi, additional, Long, Qi, additional, Lozano-Zahonero, Sara, additional, Lynch, Kristine E., additional, Mahmood, Sadiqa, additional, Makwana, Simran, additional, Mandl, Kenneth D., additional, Mao, Chengsheng, additional, Maram, Anupama, additional, Maripuri, Monika, additional, Martel, Patricia, additional, Martins, Marcelo R., additional, Marwaha, Jayson S., additional, Masino, Aaron J., additional, Mazzitelli, Maria, additional, Mazzotti, Diego R., additional, Mensch, Arthur, additional, Milano, Marianna, additional, Minicucci, Marcos F., additional, Ahooyi, Taha Mohseni, additional, Moore, Jason H., additional, Moraleda, Cinta, additional, Morris, Jeffrey S., additional, Moshal, Karyn L., additional, Mousavi, Sajad, additional, Murad, Douglas A., additional, Murphy, Shawn N., additional, Naughton, Thomas P., additional, Breda Neto, Carlos Tadeu, additional, Newburger, Jane, additional, Njoroge, Wanjiku F.M., additional, Norman, James B., additional, Obeid, Jihad, additional, Okoshi, Marina P., additional, Olson, Karen L., additional, Orlova, Nina, additional, Ostasiewski, Brian D., additional, Palmer, Nathan P., additional, Paris, Nicolas, additional, Pedrera-Jiménez, Miguel, additional, Pfaff, Ashley C., additional, Pfaff, Emily R., additional, Pillion, Danielle, additional, Pizzimenti, Sara, additional, Priya, Tanu, additional, Prokosch, Hans U., additional, Prudente, Robson A., additional, Prunotto, Andrea, additional, Quirós-González, Víctor, additional, Ramoni, Rachel B., additional, Raskin, Maryna, additional, Rieg, Siegbert, additional, Roig-Domínguez, Gustavo, additional, Rojo, Pablo, additional, Rubio-Mayo, Paula, additional, Sacchi, Paolo, additional, Sáez, Carlos, additional, Salamanca, Elisa, additional, Sanchez-Pinto, L. Nelson, additional, Sandrin, Arnaud, additional, Santhanam, Nandhini, additional, Santos, Janaina C.C., additional, Sanz Vidorreta, Fernando J., additional, Savino, Maria, additional, Schubert, Petra, additional, Schuettler, Juergen, additional, Scudeller, Luigia, additional, Sebire, Neil J., additional, Serrano-Balazote, Pablo, additional, Serre, Patricia, additional, Serret-Larmande, Arnaud, additional, Shah, Mohsin, additional, Hossein Abad, Zahra Shakeri, additional, Silvio, Domenick, additional, Sliz, Piotr, additional, Son, Jiyeon, additional, Sonday, Charles, additional, Sperotto, Francesca, additional, Spiridou, Anastasia, additional, Strasser, Zachary H., additional, Tan, Byorn W.L., additional, Tanni, Suzana E., additional, Taylor, Deanne M., additional, Terriza-Torres, Ana I., additional, Toh, Emma M.S., additional, Torti, Carlo, additional, Trecarichi, Enrico M., additional, Vallejos, Andrew K., additional, Varoquaux, Gael, additional, Vella, Margaret E., additional, Vie, Jill-Jênn, additional, Vitacca, Michele, additional, Wagholikar, Kavishwar B., additional, Waitman, Lemuel R., additional, Wang, Xuan, additional, Wassermann, Demian, additional, Wolkewitz, Martin, additional, Wong, Scott, additional, Xiong, Xin, additional, Ye, Ye, additional, Yehya, Nadir, additional, Zachariasse, Joany M., additional, Zahner, Janet J., additional, Zambelli, Alberto, additional, Zuccaro, Valentina, additional, and Zucco, Chiara, additional

Published
2023
Full Text
View/download PDF

81. A new framework for host-pathogen interaction research

Author

Yu, Hong, primary, Li, Li, additional, Huffman, Anthony, additional, Beverley, John, additional, Hur, Junguk, additional, Merrell, Eric, additional, Huang, Hsin-hui, additional, Wang, Yang, additional, Liu, Yingtong, additional, Ong, Edison, additional, Cheng, Liang, additional, Zeng, Tao, additional, Zhang, Jingsong, additional, Li, Pengpai, additional, Liu, Zhiping, additional, Wang, Zhigang, additional, Zhang, Xiangyan, additional, Ye, Xianwei, additional, Handelman, Samuel K., additional, Sexton, Jonathan, additional, Eaton, Kathryn, additional, Higgins, Gerry, additional, Omenn, Gilbert S., additional, Athey, Brian, additional, Smith, Barry, additional, Chen, Luonan, additional, and He, Yongqun, additional

Published
2022
Full Text
View/download PDF

82. The 2022 Report on the Human Proteome from the HUPO Human Proteome Project

Author

Omenn, Gilbert S., primary, Lane, Lydie, additional, Overall, Christopher M., additional, Pineau, Charles, additional, Packer, Nicolle H., additional, Cristea, Ileana M., additional, Lindskog, Cecilia, additional, Weintraub, Susan T., additional, Orchard, Sandra, additional, Roehrl, Michael H. A., additional, Nice, Edouard, additional, Liu, Siqi, additional, Bandeira, Nuno, additional, Chen, Yu-Ju, additional, Guo, Tiannan, additional, Aebersold, Ruedi, additional, Moritz, Robert L., additional, and Deutsch, Eric W., additional

Published
2022
Full Text
View/download PDF

89. Opening the Books: Follow the Money: Funding Research in a Large Academic Health Center

Author

Bourne, Henry R., Vermillion, Eric B., and Omenn, Gilbert S.

Subjects
Opening the Books Follow the Money: Funding Research in a Large Academic Health Center (Nonfiction work) -- Bourne, Henry R. -- Vermillion, Eric B. -- Book reviews, Science and technology
Abstract

Opening the Books Follow the Money: Funding Research in a Large Academic Health Center by Henry R. Bourne and Eric B. Vermillion. San Francisco, CA: University of California Medical Humanities [...]

Published
2018

91. A retrospective cohort analysis leveraging augmented intelligence to characterize long COVID in the electronic health record: A precision medicine framework.

Author

Strasser, Zachary H., Dagliati, Arianna, Shakeri Hossein Abad, Zahra, Klann, Jeffrey G., Wagholikar, Kavishwar B., Mesa, Rebecca, Visweswaran, Shyam, Morris, Michele, Luo, Yuan, Henderson, Darren W., Samayamuthu, Malarkodi Jebathilagam, Omenn, Gilbert S., Xia, Zongqi, Holmes, John H., Estiri, Hossein, and Murphy, Shawn N.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results